On SWOG study 7827, 1725 (1597 eligible) T1-3 N1 MO breast cancer patients (pts) were randomized according to menopausal status and estrogen receptor status. Median follow-up time for 633 eligible (elig) pts last known to be aJive is 15 years (maximum 21). Estrogen receptor (ER) negative (-1 pis were randomized to combination chemotherapy with cytoxan. methotrexate, 5FLI. vincristine and prednisone (CMFVP) for one year vs two years (411 elig pts, 47% with 1-3 positive nodes, 46% premenopausal). Disease free (DF) and overall survival (S) comparisons remain non-significant (logrank p=.31, .67 respectively). ER positive (+1 premenopausal pts were randomized to CMFVP for one year vs CMFVP for one year plus oophorectomy (288 elig pis, 44% with I -3 positive nodes). Results remain non-significant for this part of the study as well as for both DPS and S (logrank p=.78, .67 respectively). ER + post-menopausal pts were randomized to tamoxifen (T) for one year vs CMFVP tor one year vs CMFVP plus T for one year (898 elig pts, 51 % with 1 -3 positive nodes). Four toxic deaths were noted on the chemotherapy arms on this part of the study (2 sepsis, 1 pneumonia, 1 pneumonitis). DPS and S differences remain non-significant (3 sample logrank p=. 19, .47 respectively). The most common causes of death in the 195 pts who died without a relapse reported were cardiovascular or other cancers.
|Original language||English (US)|
|Number of pages||1|
|Journal||Breast Cancer Research and Treatment|
|State||Published - 2001|
ASJC Scopus subject areas
- Cancer Research